Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Expedia Group Inc (EXPE) vs Summit Therapeutics Inc (SMMT) Price & Performance

Expedia Group IncTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Expedia Group Inc vs Summit Therapeutics Inc — how do they compare? Expedia Group Inc trades at $326 (market cap $38.53B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Expedia Group Inc is far larger — about 3.2× Summit Therapeutics Inc's market cap, and Expedia Group Inc pays a 0.6% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

EXPESMMT
Market Cap
$38.53B$12.06B
Sector
Consumer CyclicalHealth
52-Week High
$321.07$26.98
52-Week Low
$188.51$12.55
Enterprise Value
$37.09B$11.39B
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Expedia Group Inc

Expedia Group (EXPE) trades at $328.08, up 4.48% on the day, reflecting strong momentum after Q2 2026 earnings beat. The stock shows a bullish technical trend with moving averages aligned positively, while fundamentals highlight robust revenue growth, expanding margins, and consistent earnings outperformance. Recent news emphasizes AI integration and B2B growth driving upward guidance revisions.

Outlook remains favorable with raised full-year revenue guidance and solid cash flow generation, though elevated valuation multiples and overbought RSI levels near-term pose risks. Analyst consensus leans neutral with a $322.95 price target slightly below current levels, suggesting cautious optimism amid execution and competitive pressures.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.

Returns comparison

Trailing returns across standard periods

About Expedia Group Inc

Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.

Read more on EXPE

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT